Marker Therapeutics (MRKR) Return on Equity (2016 - 2025)
Historic Return on Equity for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to 0.99%.
- Marker Therapeutics' Return on Equity fell 1800.0% to 0.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.99%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.66% for FY2024, which is 10000.0% down from last year.
- As of Q3 2025, Marker Therapeutics' Return on Equity stood at 0.99%, which was down 1800.0% from 1.17% recorded in Q2 2025.
- In the past 5 years, Marker Therapeutics' Return on Equity registered a high of 0.38% during Q4 2023, and its lowest value of 1.17% during Q2 2025.
- Its 5-year average for Return on Equity is 0.39%, with a median of 0.43% in 2022.
- In the last 5 years, Marker Therapeutics' Return on Equity skyrocketed by 11300bps in 2023 and then tumbled by -12000bps in 2024.
- Quarter analysis of 5 years shows Marker Therapeutics' Return on Equity stood at 0.15% in 2021, then tumbled by -409bps to 0.75% in 2022, then soared by 150bps to 0.38% in 2023, then plummeted by -317bps to 0.82% in 2024, then fell by -21bps to 0.99% in 2025.
- Its last three reported values are 0.99% in Q3 2025, 1.17% for Q2 2025, and 0.77% during Q1 2025.